[go: up one dir, main page]

EE200000605A - Adenoviiruse efektiivne puhastamine - Google Patents

Adenoviiruse efektiivne puhastamine

Info

Publication number
EE200000605A
EE200000605A EEP200000605A EEP200000605A EE200000605A EE 200000605 A EE200000605 A EE 200000605A EE P200000605 A EEP200000605 A EE P200000605A EE P200000605 A EEP200000605 A EE P200000605A EE 200000605 A EE200000605 A EE 200000605A
Authority
EE
Estonia
Prior art keywords
adenovirus
effective purification
solution
resin
chromatography resin
Prior art date
Application number
EEP200000605A
Other languages
English (en)
Inventor
E. Carrin Miguel
Menger Marilyn
Kovesdi Imre
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Publication of EE200000605A publication Critical patent/EE200000605A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N2030/621—Detectors specially adapted therefor signal-to-noise ratio
    • G01N2030/625—Detectors specially adapted therefor signal-to-noise ratio by measuring reference material, e.g. carrier without sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Dry Shavers And Clippers (AREA)
  • Peptides Or Proteins (AREA)
EEP200000605A 1998-04-22 1999-04-22 Adenoviiruse efektiivne puhastamine EE200000605A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8262898P 1998-04-22 1998-04-22
PCT/US1999/008843 WO1999054441A1 (en) 1998-04-22 1999-04-22 Efficient purification of adenovirus

Publications (1)

Publication Number Publication Date
EE200000605A true EE200000605A (et) 2002-04-15

Family

ID=22172352

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000605A EE200000605A (et) 1998-04-22 1999-04-22 Adenoviiruse efektiivne puhastamine

Country Status (20)

Country Link
US (3) US6383795B1 (et)
EP (1) EP1073721B1 (et)
JP (1) JP2002512361A (et)
AT (1) ATE303434T1 (et)
AU (1) AU756889B2 (et)
BG (1) BG104928A (et)
BR (1) BR9909789A (et)
CA (1) CA2328462C (et)
DE (1) DE69927013T2 (et)
EA (1) EA200001096A1 (et)
EE (1) EE200000605A (et)
HU (1) HUP0102209A2 (et)
IL (1) IL139040A0 (et)
IS (1) IS5673A (et)
MX (1) MXPA00010338A (et)
NO (1) NO20005295L (et)
PL (1) PL343630A1 (et)
SK (1) SK15682000A3 (et)
WO (1) WO1999054441A1 (et)
ZA (1) ZA200005363B (et)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP3547715B2 (ja) * 2001-03-06 2004-07-28 榮 新垣 ベクター精製用装置及び方法
ES2564553T3 (es) * 2001-08-08 2016-03-23 The Trustees Of The University Of Pennsylvania Procedimiento para purificar vectores víricos que tienen proteínas que se unen a ácido siálico
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
EP2241330A1 (en) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
CN1816619A (zh) * 2003-06-18 2006-08-09 昂尼克斯药物公司 纯化病毒的方法
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
AU2003263727A1 (en) * 2003-09-19 2005-04-11 Tinggi Technologies Private Limited Fabrication of semiconductor devices
ES2340038T3 (es) 2003-11-14 2010-05-28 Genvec, Inc. Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
WO2005080556A2 (en) * 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
JP2007532656A (ja) 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
GB0411081D0 (en) * 2004-05-18 2004-06-23 Glaxo Group Ltd Novel apparatus
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
CN101080488A (zh) * 2004-11-03 2007-11-28 因特罗根治疗公司 生产和纯化腺病毒载体的新方法
JP4626350B2 (ja) * 2005-03-22 2011-02-09 ソニー株式会社 ハイブリダイゼーション検出に適する反応部などを有する流路系、該流路系を用いるハイブリダイゼーション検出装置
EP1866338B1 (en) 2005-03-23 2016-09-21 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
AU2006233800B2 (en) * 2005-04-11 2011-07-07 Crucell Holland B.V. Virus purification using ultrafiltration
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
CA2629163C (en) 2005-11-10 2017-03-21 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
CN103172750B (zh) 2007-11-01 2014-12-10 安斯泰来制药有限公司 免疫抑制性多肽与核酸
BRPI0911377A8 (pt) * 2008-04-11 2017-12-05 Trubion Pharmaceuticals Inc Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste
NZ593235A (en) 2008-11-03 2013-02-22 Crucell Holland Bv Method for the production of recombinant adenovirus serotype 35
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
US20130195800A1 (en) 2010-03-23 2013-08-01 Intrexon Corporation Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
CA2828411A1 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
CN102590431B (zh) * 2012-02-10 2014-04-02 济南康众医药科技开发有限公司 一种治疗咳嗽的中药药物组合物检测方法
BR112017001601A2 (pt) 2014-09-07 2017-11-21 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência antiviral de modulação da expressão genética
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
CN110325203A (zh) 2017-01-07 2019-10-11 西莱克塔生物科技公司 与合成纳米载体偶联的免疫抑制剂的模式化给药
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
WO2020172509A1 (en) 2019-02-21 2020-08-27 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
KR20220015425A (ko) 2019-05-28 2022-02-08 셀렉타 바이오사이언시즈, 인크. 약화된 항바이러스 전달 벡터 면역 반응을 위한 방법 및 조성물
KR20220034191A (ko) * 2019-07-12 2022-03-17 상가모 테라퓨틱스, 인코포레이티드 빈 및 충전된 바이러스 캡시드 입자의 분리 및 정량
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788223A (en) 1985-07-26 1988-11-29 Rohm And Haas Company Low-rinse, high-capacity, weakly basic acrylic ion exchange resin
US5225989A (en) * 1988-05-19 1993-07-06 Fanuc Ltd. Apparatus and method for performing simultaneous control of control axes of a machine tool
US5228989A (en) 1989-07-06 1993-07-20 Perseptive Biosystems, Inc. Perfusive chromatography
US5019270A (en) 1989-07-06 1991-05-28 Perseptive Biosystems, Inc. Perfusive chromatography
CA2099574A1 (en) * 1991-01-04 1992-07-05 Noubar B. Afeyan Sulfonamide bonded hydrophilic coatings
US5445732A (en) 1992-06-19 1995-08-29 Sepracor Inc. Passivated porous polymer supports and methods for the preparation and use of same
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
JPH11511326A (ja) * 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
CA2184132C (en) * 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
SK181098A3 (en) * 1996-07-01 1999-07-12 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
EP0968284B1 (en) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
CZ20012428A3 (cs) 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation

Also Published As

Publication number Publication date
NO20005295L (no) 2000-11-30
MXPA00010338A (es) 2005-06-17
US20020034735A1 (en) 2002-03-21
BR9909789A (pt) 2000-12-26
AU3662099A (en) 1999-11-08
IS5673A (is) 2000-10-20
IL139040A0 (en) 2001-11-25
EP1073721B1 (en) 2005-08-31
CA2328462A1 (en) 1999-10-28
EA200001096A1 (ru) 2001-04-23
BG104928A (bg) 2001-09-28
JP2002512361A (ja) 2002-04-23
DE69927013D1 (de) 2005-10-06
SK15682000A3 (sk) 2001-05-10
US7141406B2 (en) 2006-11-28
NO20005295D0 (no) 2000-10-20
US6586226B2 (en) 2003-07-01
US6383795B1 (en) 2002-05-07
US20030203469A1 (en) 2003-10-30
WO1999054441A8 (en) 2000-02-24
ATE303434T1 (de) 2005-09-15
DE69927013T2 (de) 2006-06-29
WO1999054441A1 (en) 1999-10-28
ZA200005363B (en) 2001-09-25
HUP0102209A2 (hu) 2001-09-28
CA2328462C (en) 2010-11-09
AU756889B2 (en) 2003-01-23
PL343630A1 (en) 2001-08-27
EP1073721A1 (en) 2001-02-07

Similar Documents

Publication Publication Date Title
EE200000605A (et) Adenoviiruse efektiivne puhastamine
DK0746398T3 (da) Antistofrensning
DE69417617D1 (de) Kolonne für Flüssigkeitschromatographie
BRPI9910332B8 (pt) método para purificação de um polipeptídio a partir de uma composição
DE3580460D1 (de) Gemischte phenylendiester als persaeurevorlaeufer.
DE69837463D1 (de) Navigation durch fernsehprogramme
DE69435170D1 (de) Extrakorporeale Vorrichtungen zur Adsorption durch Affinität
DE3580057D1 (de) Heterocylische mercaptocarbonsaeureamide, -imide und -nitrile als korrosionsinhibitoren.
DE3586068D1 (de) Fluessigkeitschromatographiesaeule.
DE3584763D1 (de) Fluessigkeitschromatograph.
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
NO165570C (no) Dekoderingssystem for personsoeker.
AU1378395A (en) Metal chelators
MX9203631A (es) Proteinas succiniladas que contienen hierro.
ATE389023T1 (de) Kontrolle der schotendehiszenz
IT8448311A0 (it) Fermaglio sganciabile
KR850009561U (ko) 자전거형 새들 조립체용 고정장치
DE3688808D1 (de) Fluessigmetall-ionenquelle.
DK1062244T3 (da) Forbedrede fremgangsmåder til fremstilling af faktor VIII proteiner
PT840746E (pt) Metodo para purificacao de proteinas
DE69509390D1 (de) Flüssigmetallionenquelle
DK285984A (da) Sadellejring
DK242885A (da) Apparat til overtraekning af soede sager
ATE115630T1 (de) Trennung von antikörpern gegen metallchelate.
DE3484167D1 (de) Legierung enthaltende fluessigmetall-ion-arten.